Synthesis and biological activity of new pyridone diaryl ether non-nucleoside inhibitors of HIV-1 reverse transcriptase

New pyridone non-nucleoside reverse transcriptase inhibitors (NNRTIs) were prepared and several flexible routes to this class of inhibitor were identified. These NNRTIs were active inhibitors of the replication of wild-type and NNRTI-resistant HIV. Structure-based drug design was used to optimize the activity of the compounds against NNRTI-resistant mutants. The co-crystal structure of inhibitor 2b in the NNRTI binding pocket of HIV reverse transcriptase (HIVRT) is also described.

[1]  K. Hertogs,et al.  Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents. , 2009, Journal of medicinal chemistry.

[2]  Y. Li,et al.  Diphenyl Ether Non‐Nucleoside Reverse Transcriptase Inhibitors with Excellent Potency Against Resistant Mutant Viruses and Promising Pharmacokinetic Properties , 2009, ChemMedChem.

[3]  Taraneh Mirzadegan,et al.  Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase. , 2008, Journal of medicinal chemistry.

[4]  Y. Li,et al.  Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2008, Bioorganic & medicinal chemistry letters.

[5]  Yu Li,et al.  Discovery of triazolinone non-nucleoside inhibitors of HIV reverse transcriptase. , 2008, Bioorganic & medicinal chemistry letters.

[6]  Charles Flexner,et al.  HIV drug development: the next 25 years , 2007, Nature Reviews Drug Discovery.

[7]  F. Maggiolo,et al.  Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring Mutations in NNRTI- or PI-Treated Patients , 2007, HIV clinical trials.

[8]  J. Medina-Franco,et al.  Pyridin‐2(1H)‐ones: A Promising Class of HIV‐1 Non‐nucleoside Reverse Transcriptase Inhibitors , 2007, ChemMedChem.

[9]  P. Wolschann,et al.  Structural Aspects of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibition , 2007 .

[10]  F. Wit,et al.  Efavirenz: a review , 2007, Expert opinion on pharmacotherapy.

[11]  Christophe Meyer,et al.  Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. , 2005, Journal of medicinal chemistry.

[12]  M. Schlosser,et al.  Regiochemically flexible substitutions of di-, tri-, and tetrahalopyridines: the trialkylsilyl trick. , 2005, The Journal of organic chemistry.

[13]  R. Grubbs,et al.  Synthesis of functionalized vinyl boronates via ruthenium-catalyzed olefin cross-metathesis and subsequent conversion to vinyl halides. , 2003, The Journal of organic chemistry.

[14]  D I Stuart,et al.  Binding of the Second Generation Non-nucleoside Inhibitor S-1153 to HIV-1 Reverse Transcriptase Involves Extensive Main Chain Hydrogen Bonding* , 2000, The Journal of Biological Chemistry.

[15]  L. Hasvold,et al.  Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents. , 1996, Journal of medicinal chemistry.

[16]  Paul R. Gerber,et al.  MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry , 1995, J. Comput. Aided Mol. Des..

[17]  Chun-Shan Wang.  Structure and chemistry of 4‐hydroxy‐6‐methyl‐2‐pyridone , 1970 .